Literature DB >> 29746284

The concept of oligometastases in colorectal cancer: from the clinical evidences to new therapeutic strategies.

Edouard Massaut1, Ali Bohlok1, Valerio Lucidi2, Alain Hendlisz3, Jean A Klastersky3, Vincent Donckier1.   

Abstract

PURPOSE OF REVIEW: The concept of oligometastases, defining cancers with limited metastatic capacity and attaining a limited number of secondary sites, is now widely accepted, particularly in colorectal cancer. Currently, however, accurate predictive markers for oligometastatic tumors are still lacking. For this reason, it remains challenging to translate this concept into clinical recommendations. In the present work, we review recent publications on oligometastases in colorectal cancer, showing the evidences for such presentation and underlying the need for the identification of biomarkers, necessary to further develop new therapeutic strategies. RECENT
FINDINGS: This review of recently published series confirms that long-term survival and cure could be obtained in patients undergoing surgical resection for colorectal metastases, particularly in the cases of liver metastases. Similar results are observed in other secondary sites such as in pulmonary metastases. Furthermore, in patients with unresectable metastases, significant survival benefit could be still obtained using nonresectional targeted approaches, as thermal ablation or stereotactic radiotherapy. Although these clinical evidences could now serve as proof-of-concept for the existence of an oligometastatic phenotype in colorectal cancer, neither clinical characteristics nor biological biomarkers have been established to be able to prospectively define the patients that will benefit from such therapeutic approaches targeting the metastatic sites. This emphasizes the need for further studies aiming at better defining early clinical and biological characteristics of these patients. As, currently, the reliable identification of the oligometastatic patients could only rely on the demonstration of favorable long-term outcomes after metastases-directed therapies, we propose that retrospective studies will be pivotal to analyze this question.
SUMMARY: Extensive research is undergoing to define biologically the oligometastatic phenotype in colorectal cancer. Currently, the selection of the patients for potentially curative metastasectomy remains mostly empirical.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29746284     DOI: 10.1097/CCO.0000000000000453

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  9 in total

1.  Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.

Authors:  Selina K Wong; Lovedeep Gondara; Daniel J Renouf; Howard J Lim; Jonathan M Loree; Janine M Davies; Sharlene Gill
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization.

Authors:  Michal Mauda-Havakuk; Elizabeth Levin; Elliot B Levy; Venkatesh P Krishnasamy; Victoria Anderson; Nidhi Jain; Hayet Amalou; Tito Fojo; Maureen Edgerly; Paul G Wakim; Marybeth S Hughes; Jaydira Del Rivero; Bradford J Wood
Journal:  Cancer Med       Date:  2021-03-09       Impact factor: 4.711

3.  Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis.

Authors:  Kangpyo Kim; Tae Hyung Kim; Tae Hyun Kim; Jinsil Seong
Journal:  J Hepatocell Carcinoma       Date:  2021-02-11

Review 4.  Molecular Mechanisms Related with Oligometastatic Prostate Cancer-Is It Just a Matter of Numbers?

Authors:  Cristian Surcel; Alexander Kretschmer; Cristian Mirvald; Ioanel Sinescu; Isabel Heidegger; Igor Tsaur
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

5.  Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer.

Authors:  Alexander Philipovskiy; Reshad Ghafouri; Alok Kumar Dwivedi; Luis Alvarado; Richard McCallum; Felipe Maegawa; Ioannis T Konstantinidis; Nawar Hakim; Scott Shurmur; Sanjay Awasthi; Sumit Gaur; Javier Corral
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

6.  Long-term survival results after treatment for oligometastatic brain disease.

Authors:  Carsten Nieder; Mandy Hintz; Ilinca Popp; Angelika Bilger; Anca L Grosu
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-04

Review 7.  Prognostic and Predictive Biomarkers in Oligometastatic Disease.

Authors:  Kevin J Barnum; Sarah A Weiss
Journal:  Cancer J       Date:  2020 Mar/Apr       Impact factor: 2.074

8.  Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer.

Authors:  Jung Yoon Choi; Sunho Choi; Minhyeok Lee; Young Soo Park; Jae Sook Sung; Won Jin Chang; Ju Won Kim; Yoon Ji Choi; Jin Kim; Dong-Sik Kim; Sung-Ho Lee; Junhee Seok; Kyong Hwa Park; Seon Hahn Kim; Yeul Hong Kim
Journal:  Cancer Res Treat       Date:  2020-02-16       Impact factor: 4.679

Review 9.  How we treat metastatic colorectal cancer.

Authors:  Vincenzo De Falco; Stefania Napolitano; Susana Roselló; Marisol Huerta; Andrés Cervantes; Fortunato Ciardiello; Teresa Troiani
Journal:  ESMO Open       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.